YL 201
Alternative Names: YL-201Latest Information Update: 07 May 2024
At a glance
- Originator MediLink Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
- Phase I/II Solid tumours
Most Recent Events
- 30 Apr 2024 MediLink Therapeutics plans a phase I trial in Solid tumours (Combination therapy, Late-stage disease) in China (IV) (NCT06394414)
- 22 Feb 2024 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06241846)
- 06 Feb 2024 MediLink Therapeutics plans a phase II trial for Prostate Cancer (Hormone refractory, Metastatic disease) in China (IV) in February 2024 (NCT06241846)